huIL33 Mouse
製品名
huIL33 Mouse
製品ID
C001722
系統名
C57BL/6NCya-Il33em1(hIL33)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huIL33 Mouse（カタログ番号C001722）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
DVS27, IL1F11, NF-HEV, NFEHEV, C9orf26
NCBI ID
染色体
Chr 9
MGI ID
さらに
系統詳細
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that operates as a crucial "alarmin" molecule within the immune system [1]. Released by epithelial and endothelial cells, as well as other cell types, upon cellular damage or stress, IL-33 signals through its receptor, the IL1RL1/ST2 heterodimer, expressed on various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and innate lymphoid cells type 2 (ILC2s). Receptor engagement activates downstream signaling pathways, notably NF-κB and MAPK, culminating in the production of type 2 cytokines such as IL-4, IL-5, and IL-13, thereby promoting Th2 cell differentiation and orchestrating type 2 immune responses critical for defense against helminths and in allergic inflammation [1-2]. Constitutive expression of IL-33 in barrier tissues positions it as a sentinel, contributing to tissue homeostasis and rapidly responding to environmental insults [3]. Aberrant expression and signaling of IL-33 have been strongly implicated in the pathogenesis of a spectrum of inflammatory conditions, including asthma, atopic dermatitis, allergic rhinitis, and inflammatory bowel disease, highlighting its significance as a potential therapeutic target in these disorders [4].
The huIL33 mouse is a humanized model constructed by replacing the sequence of the mouse Il33 gene in situ with the corresponding sequence from the human IL33 gene. The huIL33 mice can be used for studies on asthma, atopic dermatitis, allergic rhinitis, inflammatory bowel disease, and other inflammatory disorders, as well as for IL33-targeted drug development.
参考文献
Shakerian L, Kolahdooz H, Garousi M, Keyvani V, Kamal Kheder R, Abdulsattar Faraj T, Yazdanpanah E, Esmaeili SA. IL-33/ST2 axis in autoimmune disease. Cytokine. 2022 Oct;158:156015.
Kudo-Saito C, Miyamoto T, Imazeki H, Shoji H, Aoki K, Boku N. IL33 Is a Key Driver of Treatment Resistance of Cancer. Cancer Res. 2020 May 15;80(10):1981-1990.
Zhou Z, Yan F, Liu O. Interleukin (IL)-33: an orchestrator of immunity from host defence to tissue homeostasis. Clin Transl Immunology. 2020 Jun 17;9(6):e1146.
Cayrol C. IL-33, an Alarmin of the IL-1 Family Involved in Allergic and Non Allergic Inflammation: Focus on the Mechanisms of Regulation of Its Activity. Cells. 2021 Dec 30;11(1):107.
系統作製戦略
The sequences from ATG start codon to TAA stop codon of the endogenous mouse Il33 gene were replaced with the sequences from ATG start codon to TAG stop codon of the human IL33 gene.
Figure 1. Gene editing strategy of huIL33 Mice.
適用分野
IL33-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of asthma, atopic dermatitis, allergic rhinitis, and inflammatory bowel disease;
Research on other inflammatory disorders.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。